🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Akebia Therapeutics, Inc. AKBA R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.akebia.com
Company Profile ↓
$1.38
-65.24% 1Y
Mkt Cap$370.20M
P/E-17.25
P/B9.06
52W High$4.01
52W Low$0.87
Book Value$0.10
EPS (TTM)$-0.08

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 31.4% per year over the last five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $236.20M (+47.5% YoY); net profit $-5.34M.
  • Trailing 12 Months Year-on-year growth — revenue -6.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR -6.9%, profit CAGR 31.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-6.88%
1 Year:-6.60%

Compounded Profit Growth

5 Years:31.44%
1 Year:-

Stock Price Performance

1 Year:-65.24%
6 Months:-1.43%
3 Months:-11.54%
1 Month:+49.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 16% of range
$0.87 $4.01
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)67.55 · Neutral
Price Performance
1M+49.19%
3M-11.54%
6M-1.43%
1Y-65.24%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 31.4% over 5 years.
  • Generates positive free cash flow.

CONS

  • Revenue declined at -6.9% CAGR over 5 years.
  • Trading 65.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-17.25
Industry PE
25.88
Forward P/E
-7.26
PEG Ratio
-
Book Value
$0.10
Price to Book
9.06
P/S
1.07
EV/EBITDA
23.32
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-6.88%
Profit 5Y
31.44%
Revenue (YoY)
-6.60%
Earnings (YoY)
-

Profitability & Returns

ROCE
9.58%
ROE
-78.95%
ROA
2.02%
Profit Margin
-8.83%
Op Margin
-2.76%
Gross Margin
81.94%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-0.08

Balance Sheet & Liquidity

Debt/Equity
7.22
Quick Ratio
1.29
Current Ratio
1.40
Debt
$197.52M
Total Assets
$362.52M
Current Assets
$243.48M
Working Capital
$90.02M

Ownership

Promoter Holding
4.06%
Chg in Prom Hold
-
FII / Inst Holding
42.12%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$370.20M
Total Revenue (TTM)
$232.40M
EBITDA
$12.13M
Free Cash Flow
$65.81M
Operating Cash Flow
$60.37M
Shares Outstanding
268.26M
Gross Margin
81.94%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AKBA Akebia Therapeutics, Inc. R2K 1.38 -17.25 $370.20M 0.00% 9.58% -78.95% -6.88% 31.44%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------28.52M41.28M-45.93M48.79M53.17M-72.67M100.80M91.98M-88.48M90.14M59.99M-52.30M52.91M48.76M61.70M126.36M48.71M40.01M56.38M42.05M32.61M43.65M--57.34M62.47M58.77M57.62M53.54M
Cost of Revenue -----------------------------------7.62M9.92M9.38M12.54M12.29M
Gross Profit -----------------------------------49.71M52.55M49.38M45.09M41.25M
Operating Expenses -----------------------------------36.20M38.46M44.93M53.64M45.95M
Operating Income -19.68M-20.05M-26.05M-36.19M-36.18M-38.04M-44.97M-22.14M-24.18M14.61M-24.50M-35.66M-27.84M-90.16M-75.97M-59.52M-55.91M-94.89M-59.12M-173.82M-58.09M-85.40M-64.94M-79.34M-54.89M-59.58M34.08M-50.41M-25.60M-9.00M-13.04M-14.94M-8.72M--13.51M14.09M4.45M-8.55M-4.70M
EBITDA -----------------------------------14.20M7.40M6.22M-6.09M-3.91M
Interest Expense -----------------------------------7.77M6.83M4.75M4.83M4.69M
Pretax Income -----------------------------------6.11M247.00K1.16M-11.23M-8.93M
Tax Provision ---------------------------------0-0-615.00K1.01M126.00K
Net Income -19.48M-19.86M-25.80M-35.78M-36.31M-37.86M-44.54M-21.52M-23.13M15.52M-23.42M-34.07M-26.05M-60.05M-72.42M-58.17M-54.59M-94.48M-60.75M-175.75M-59.96M-87.00M-69.58M-83.04M-59.54M-63.51M29.45M-54.10M-26.88M-11.17M-14.49M-17.98M-8.58M--6.11M247.00K540.00K-12.24M-9.05M
Diluted EPS -------1.15-0.53-0.490.31----------1.28-0.42--0.45-0.51-0.34-0.350.15-0.29-0.15-0.06-0.08-0.09-0.04--0.030.000.00-0.05-0.03
R&D Expense 15.60M-20.23M30.88M31.24M-60.05M43.75M58.71M-61.40M71.92M70.63M-82.35M85.69M74.51M-81.23M52.82M46.86M-40.61M37.21M40.47M43.83M26.03M28.03M19.69M20.20M13.33M9.73M7.65M8.49M-9.75M11.01M14.94M-14.81M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --001.53M181.23M207.74M335.00M295.31M-292.48M194.62M160.18M236.20M
Cost of Revenue ----------85.57M74.15M63.18M39.46M
Gross Profit ----------206.92M120.47M97.00M196.73M
Operating Expenses ----------271.76M166.55M147.42M173.24M
Operating Income -8.52M-15.93M-37.94M-61.51M-136.46M-76.67M-178.16M-286.29M-376.44M--64.85M-46.08M-50.41M23.50M
EBITDA -----------40.84M-8.27M-13.72M21.73M
Interest Expense ----------15.69M6.03M18.18M24.18M
Pretax Income -----------94.23M-51.92M-69.41M-3.72M
Tax Provision ----------0001.62M
Net Income -8.20M-13.17M-37.03M-60.72M-135.75M-73.67M-143.59M-279.66M-383.46M--94.23M-51.92M-69.41M-5.34M
Diluted EPS --------2.36-2.77--0.51-0.28-0.33-0.02
R&D Expense 5.63M8.90M23.26M43.02M115.78M230.89M291.01M322.97M218.49M147.85M129.99M63.08M37.65M62.36M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --34.66M111.00M142.94M300.22M364.25M996.54M771.20M644.14M-356.05M241.70M220.67M376.56M
Current Assets -----------185.18M118.15M113.83M252.96M
Cash & Equivalents 5.01M1.64M21.21M32.78M49.78M187.34M70.16M104.64M147.45M228.70M-90.47M42.92M51.87M184.84M
Inventory -----------21.57M15.69M16.24M15.61M
Receivables -----------40.28M39.29M34.37M47.03M
Total Liabilities --3.91M6.92M11.94M232.10M241.67M360.61M376.44M396.52M-350.82M272.29M269.86M343.95M
Current Liabilities --3.90M6.88M11.87M114.27M141.11M265.69M208.12M187.15M-129.54M99.87M80.91M162.94M
Long Term Debt --------75.81M96.38M-34.08M17.18M38.69M48.25M
Total Debt -----------99.78M48.12M47.64M51.80M
Total Equity -48.19M-59.59M-127.07M104.08M131.00M68.12M122.57M635.93M394.76M247.62M-5.23M-30.58M-49.19M32.61M
Shares Outstanding -----------184.14M194.58M224.85M265.42M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ---57.91M-56.16M-97.49M-257.44M-110.39M--73.15M-23.38M-40.66M67.99M
Investing Cash Flow ---12.71M-177.26M36.59M211.18M-40.00M--114.00K0-33.00K-7.93M
Financing Cash Flow ---66.95M116.24M96.56M88.97M231.72M-14.60M-25.21M49.66M72.93M
Capital Expenditure -19.00K-229.00K-414.00K-2.66M-1.62M-1.61M-6.66M-317.00K-59.00K-114.00K--33.00K-8.10M
Free Cash Flow ---55.24M-57.78M-99.10M-264.10M-110.70M--73.27M-23.38M-40.69M59.89M
Net Change in Cash ----------58.67M-48.59M8.97M132.99M
Share Buybacks -162.00K-----------

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------70.7%61.9%60.6%83.3%
Operating Margin % -----8,889.9%-42.3%-85.8%-85.5%-127.5%--22.2%-23.7%-31.5%9.9%
Net Margin % -----8,843.5%-40.7%-69.1%-83.5%-129.9%--32.2%-26.7%-43.3%-2.3%
ROE % 13.8%10.4%-35.6%-46.3%-199.3%-60.1%-22.6%-70.8%-154.9%--1,801.6%169.8%141.1%-16.4%
ROCE % --51.8%-36.4%-46.9%-73.4%-34.4%-24.4%-50.8%-82.4%--28.6%-32.5%-36.1%11.0%

Shareholding Pattern

Insiders
4.06%
Institutions
42.12%
Public Float
-

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AKBA

Yahoo Finance hu, 02 Jul 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3 newly-hired employees options to…

Yahoo Finance ue, 30 Jun 2026

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list. TheFly reported on June 10 that AKBA strengthened the in…

Yahoo Finance ue, 30 Jun 2026

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Commi…

Yahoo Finance Wed, 10 Jun 2026

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Additional Orange Book Listed Patent Secured and Composition of Matter Patent is Eligible for 5-Year ExtensionCAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with th…

Yahoo Finance Fri, 05 Jun 2026

Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global …

Yahoo Finance hu, 28 May 2026

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief …

AKBA — Frequently Asked Questions

What is the current share price of Akebia Therapeutics, Inc. (AKBA)?

As of 2026-07-15 16:51 PDT, Akebia Therapeutics, Inc. (AKBA) trades at $1.38 on NasdaqCM. Its 52-week range is $0.87 to $4.01.

What is the market capitalisation of AKBA?

Akebia Therapeutics, Inc. (AKBA) has a market capitalisation of $370.20M on NasdaqCM.

What is the P/E ratio of AKBA?

AKBA trades at a trailing price-to-earnings (P/E) ratio of -17.25. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 9.06.

What is the return on equity (ROE) of AKBA?

AKBA has a return on equity (ROE) of -78.95%. Its return on capital employed (ROCE) is 9.58%.

Is AKBA a good stock to buy?

This page provides a data-driven analysis of Akebia Therapeutics, Inc. (AKBA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space